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Abstract: In HIV patients who discontinue highly active antiretroviral therapy (HAART), the degree of HIV RNA sup-
pression at the time of treatment interruption may predict success of re-treatment after the interruption (STI). A case-
control substudy of the Staccato trial in Thailand included CD4-guided STI subjects with HIV RNA > 50 copies /ml (vi-
rological failure cases, n=11) and HIV RNA < 50 copies/ml (controls, n=22) after 12-24 weeks of HAART re-treatment 
following a median of 2 STI cycles. Controls were matched for age, gender and pre-ART CD4 count. HIV RNA with 5 
copies/ml detection limit was determined on pre-virological failure samples. HIV RNA increased in cases compared to 
controls with each successive STI cycle (p-trend across time-points 0.004). The last HIV RNA below 50 copies/ml was 
significantly higher among cases compared to controls (p=.004). Measuring HIV RNA below 50 copies/ml may be useful 
in predicting virological failure to STI. 
INTRODUCTION 
  HIV-RNA quantification is a sensitive indicator of the 
effectiveness of highly active antiretroviral therapy 
(HAART). HIV RNA measurements 2-6 months after treat-
ment initiation correlate with long-term virological outcomes 
[1, 2]. Successful HAART is generally defined as HIV RNA 
suppression to below 50 copies/ml although low level repli-
cation continues even when HIV RNA is undetectable by 
conventional assays [3-5]. 
  Staccato investigated CD4-guided structured treatment 
interruption (STI) of HAART and found that the rate of viro-
logical failure was low (2%) and similar to those who took 
HAART continuously [6]. While most STI patients in our 
study achieved HIV RNA suppression below 50 copies/ml 
following HAART re-treatment, it is possible that slow rises 
in HIV RNA with successive STI cycles occur and result in 
subsequent virological failure in some patients. In this sub-
study, we investigated the value of a modified version of the 
Roche AMPLICOR Monitor 1.5 protocol with a limit of   
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detection of 5 copies/ml, in predicting virological failure 
after STI. We hypothesized that compared to patients with 
HIV RNA < 5 copies/ml, those with HIV RNA between 5-49 
copies/ml following HAART re-treatment were more likely 
to have virological failure after CD4-guided STI. 
MATERIALS AND METHODS 
Study Population 
  This was a sub-study of the Staccato Trial which was 
performed in Thailand only (n=379, 77% of the total Stac-
cato population). The study design is shown in Fig. (1). In 
brief, Staccato enrolled HAART-treated patients with HIV 
RNA < 50 copies/ml and CD4 counts > 350 cells/l and ran-
domized them in a 2:1 fashion to CD4-guided STI, resuming 
HAART only when CD4 count fell below 350 cells/ l (STI 
arm, n=238 in Thailand) and continuous treatment (n=118 in 
Thailand) with their existing HAART regimen. Following a 
median time of 21.9 months after randomization, all patients 
received 12 to 24 weeks of HAART and HIV RNA response 
to re-treatment was determined.  The HAART regimen in 
Thai patients was 2 nucleoside reverse transcriptase inhibi-
tors + ritonavir-boosted saquinavir. Thai patients were 
antiretroviral-naïve prior to enrollment and received HAART 
for at least 24 weeks until they fulfilled the randomization 
criteria. All patients provided written informed consent. The 
study was approved by the Thai national and local institu-70    The Open Virology Journal, 2008, Volume 2  Langford et al. 
tional review boards. This study is registered at ClinicalTri-
als.gov with the identifier NCT00113126. 
Definition of Cases and Controls 
 Cases: Patients with a virological failure in the STI arm 
from Staccato: HIV RNA > 50 copies/ml after 24 weeks of 
HAART re-treatment following CD4-guided STI. 
 Controls: Patients without virological failure after 12 to 
24 weeks of HAART re-treatment following CD4-guided 
STI: HIV RNA 50 copies/ml at 12 or 24 weeks (if HIV 
RNA at 12 weeks was above 50 and under 500 copies/ml). 
Two controls were matched per case by gender, age (±3 
years), pre-treatment CD4 count (± 50 cells). 
Study Time-Points 
  “Entry” corresponds to the baseline visit, before HAART 
was stopped for the first time. The first cycle of re-treatment 
period lasts from randomization to the day when patients 
achieved suppressed HIV RNA with HAART following their 
first STI. Similarly, the second cycle of re-treatment lasts 
from the second treatment stop to the day of HIV RNA sup-
pression with HAART following the second STI. The last 
HIV RNA below 50 copies/ml described the last time point 
with HIV RNA below 50 copies/ml prior to the protocol-
mandated HAART re-treatment period at the end of the trial. 
The end of the re-treatment period corresponded to the end 
of Staccato trial, i.e. after 12 to 24 weeks of re-treatment. For 
cases, this corresponded to the time when they failed to sup-
press HIV RNA below 50 copies/ml. 
Modified HIV RNA Assay 
  The COBAS AMPLICOR Monitor Version 1.5 (Roche, 
Nutley, USA) was modified to lower the detection limit of 5 
copies/ml [3]. In order to increase the initial viral RNA in-
put, plasma samples of 1.1ml were centrifuged at 50,000g at 
4°C for 90 minutes before RNA extraction. Following re-
moval of the supernatant, the only alterations to the manu-
facturers' protocol for the Ultrasensitive assay were a de-
crease in the volume of internal quantitative standard 
(6.25μL vs 25μL), a reduction in the volume of specimen 
diluent (55μL vs 400μL) and extension of the substrate incu-
bation time (15 minutes vs 10 minutes). 
Statistical Analysis 
  Cases and controls (1:2) were compared at baseline re-
garding demographical and clinical variables using univari-
 
Fig. (1). The study design. HAART (highly active antiretroviral therapy), STI (structured treatment interruption), CT (Continuos Treatment) 
virological failure cases were defined as patients who had HIV RNA > 50 copies/ml after 24 weeks of HAART re-treatment following CD4-
guided STI, non-virological failure controls were defined as patients with HIV RNA  50 copies/ml after 12-24 weeks of HAART re-
treatment who were matched with virological failure cases by gender, age and pre-treatment CD4 count. 
379 Thai patients with CD4 > 350 cells/µl and 
HIV RNA < 50 copies/ml randomized
238 assigned to STI
HAART stopped Entry
HAART re-started when 
CD4 < 350 cells/µl and 
stopped again when CD4 ≥
350 cells/µl
All patients received 
continuous HAART for 12-24 
weeks
Virological failure cases 
(n=11)
STI treatment cycles
End of trial
Non-virological failure 
controls (n=22)
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ate conditional logistic regression to compare qualitative 
variables and Wilcoxon matched-pairs signed-rank test for 
quantitative variables. The case-control population was also 
compared to the entire Thai population included in the STI 
arm of Staccato using unmatched a non parametric test 
(Mann Whitney) for quantitative data and Fischer’s exact 
test for qualitative data. 
  P-test for linearity across the study time-points was as-
sessed using ANOVA. 
  In order to determine whether the last available HIV 
RNA above 5 copies/ml was a predictive factor for virologi-
cal failure at the end of Staccato, conditional logistic regres-
sion was performed using a backward stepwise procedure. 
Each independent variable with a p-value<0.25 at univariate 
analysis was included in the multivariate model and vari-
ables were removed one by one, leaving those with a p-
value<0.10. 
  SPSS 15.0 (SPSS Inc. Chicago, Illinois, USA) and 
STATA 8 Statistical Softwares (StataCorp LP, Texas, USA) 
were used to perform analyses. 
RESULTS 
  We included 11 cases and 22 controls. The baseline char-
acteristics of cases and controls are presented in Table 1 and 
compared to those of the Thai population included into Stac-
cato and randomized in the STI arm. Cases and controls 
were similar, except that cases had significantly more STI 
cycles than controls (p=0.02). The case-control population 
was similar to the entire Thai population included in the STI 
arm of Staccato, except that Thai patients were significantly 
older than patients selected in the case-control study 
(p=0.04). 
 Table  2 shows the median HIV RNA values for the cases 
and controls, with their interquartile range (IQR), at each STI 
re-treatment cycle. In cases, the median (IQR) duration of 
the first and the second STI cycles weres 24 and 36 weeks 
respectively. In controls, the median duration of the first 
cycle was 12 weeks, and 24 weeks for the second cycle. Us-
ing modified HIV RNA HIV RNA assay with a detection 
limit of 5 copies/ml, we did not find any difference between 
cases and controls on log10 HIV RNA at entry (p=0.24). 
After the first cycle of re-treatment, there was a trend to a 
higher HIV RNA in cases compared to controls (p=0.06). 
After the second cycle of re-treatment, there was no signifi-
cant difference cases and controls regarding the median HIV 
RNA (p=0.32). When we used the last available HIV RNA 
below 50 copies/ml for cases and controls, we found that 
cases had a significantly higher median HIV RNA than the 
controls (p=0.004). Variations in trend across study time-
points showed a significant increase in log10 HIV RNA (p-
trend=0.004) only due to a significant increase in cases (p-
trend<0.001 vs 0.55 in controls). 
  By univariate and multivariate conditional logistic re-
gression model, there was a trend for a higher probability of 
final virological failure when the last available HIV RNA 
was between 5-49 copies/ml compared to HIV RNA below 5 
copies/ml (OR 7.77, 95%CI 0.89-67.5, p=0.06). There was 
no significant association between the risk to have HIV RNA 
between 5-49 copies/ml and risk factor, CDC classification 
and pre-HAART CD4. 
DISCUSSION 
  With each successive treatment interruption, the differ-
ences in median HIV RNA between virological failure cases 
and controls increased, reaching statistical significance with 
the last available HIV RNA prior to the protocol-mandated 
HAART re-treatment at the end of the trial. This finding 
implies that over the course of multiple interruptions there is 
a trend towards higher residual viremia amongst those who 
ultimately experienced treatment failure than in those who 
maintained low HIV RNA. 
  Our result is similar to the ISS PART study which 
showed increased residual HIV viremia between 2.5 to 50 
copies/ml in virological failure cases after two years of a 
step-wise fixed time strategy with five STIs of one, one, 2, 2 
Table 1.  Characteristics of STI Participants in this Substudy and in the Whole Staccato Thai Cohort 
 
Characteristics  Cases  
(n=11) 
Controls  
(n=22)  p-Value  Staccato STI Thai Cohort  
(n=238)  p-Value 
Median age in years (IQR)  33.5 (31-38)  32.5 (29-36.5)  0.52  34.5 (29.9-40.0)  0.04 
Gender (% male)  11 (100)  22 (100)  0.99  105 (44.1)  0.33 
Mode of transmission (%) 
MSM 
Heterosexual 
 
2 (18.2) 
9 (81.8) 
 
2 (9.1) 
20 (90.9) 
0.43  
27 (11.3) 
206 (86.6) 
0.99 
CDC stage (%) 
CDC A 
CDC B 
CDC C 
 
6 (54.6) 
5 (45.4) 
0 
 
15 (68.2) 
6 (27.3) 
1 (4.5) 
 
- 
0.19 
0.99 
 
146 (61.3) 
79 (33.2) 
13 (5.5) 
0.99 
Median pre-STI CD4 cells/μL (IQR)  463 (398-570)  433 (369-570)  0.18  463 (399-553)  0.42 
Median pre-ARV CD4 cells/μL (IQR)  265 (200-308)  250 (242-316)  0.63  261 (210-325)  0.89 
Median pre-ARV HIV RNA (log10 copies/mL) (IQR)  5.08 (4.47-5.31)  4.81 (4.42-5.16)  0.20 4.7  (4.3-5.2)  0.38 
Median number of STI cycles (IQR)  2 (1-2)  1 (1-2)  0.02  2 (1-3)  0.57 
IQR: interquartile range, STI: structured treatment interruption, MSM: Men who have sex with men, ARV: Antiretroviral therapy. 72    The Open Virology Journal, 2008, Volume 2  Langford et al. 
and 3 months’ duration, each followed by 3 months of 
HAART [7]. The ISS PART subjects were different to the 
Staccato subjects. They were mostly antiretroviral-pre 
treated and had archived resistance mutations. The Staccato 
Thai subjects were HAART-naïve and likely had no archived 
mutations [6]. This illustrates that the finding of increased 
residual viremia after STI may apply to both those with and 
without pre-existing risk for virological failure. 
  The treatment failures seen after STI have mostly been 
attributed to the replication of archived resistant quasispecies 
that existed in proviral DNA prior to STI. Selection of new 
mutations have been reported in some studies especially 
those that use antiretrovirals with low resistance threshold 
such as lamivudine and non-nucleoside reverse transcriptase 
inhibitors [8, 9]. The short duration of HAART-retreatment 
after each STI cycle may be inadequate to control HIV viral 
replication in viral reservoirs and compartments. 
  Currently, the goal of HAART is to maintain HIV RNA 
below 50 copies/ml [2]. Studies have shown continued viral 
replication at levels below 50 copies/ml despite HAART [3, 
4]. Palmer et al. used an HIV-1 RNA assay with single-copy 
sensitivity to show that 77% of 40 HAART-treated patients 
with HIV RNA below 50 copies/ml for at least 2 years had 
detectable low-level viremia, and that all patients had at least 
one sample with detectable viremia [4]. The significance of 
this finding is unclear. It may explain the viral blips that oc-
curs frequently but do not appear to lead to virological fail-
ure with both protease inhibitor and non-nucleoside reverse 
transcriptase treatments [10-12]. Continued viremia at vary-
ing HIV RNA levels albeit below 50 copies/ml may have 
different effects on the HIV reservoirs. Persistence of viral 
reservoir particularly the latently infected CD4+ T cells has 
been a major obstacle to HIV eradication [13, 14]. With new 
HAART becoming more effective, it is possible that in the 
future suppressing HIV to the lowest possible level using 
HIV RNA monitoring assay such as that in our study may be 
desired in an attempt to limit the chance of HIV rebound and 
the size of HIV reservoir. 
  Our study is limited by its small sample size and the 
highly selective nature of the case-control matching which 
may limit the generalizability of the results to other popula-
tions. Nevertheless, by utilizing a modified HIV RNA 
method, we demonstrated that a higher residual viremia be-
tween 5 and 50copies/ml after HAART re-treatment may 
predict those who would ultimately experienced treatment 
failure from STI. 
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Table 2.  Median HIV RNA in Copies/ml (Interquartile Range) Between Cases and Controls After HAART Re-Treatment 
 
Cases Controls 
Time Points 
Median IQR  Median  IQR 
P Value* 
Entry   5  5-17  5  5-10  0.24 
1
st HAART re-treatment  15  11-24  5  5-15  0.06 
2
nd HAART re-treatment  29   28-30  5  5-10  0.32 
Last available HIV RNA < 50 copies/ml  17  8-28  5  5-11  0.004 
Last HAART re-treatment at the end of the trial  190  98-470  5  5-11  <0.001 
*We provided p-value from Wilcoxon signed-rank test on values expressed in log10 copies/ml. Supersensitive Viral Load Assay  The Open Virology Journal, 2008, Volume 2    73 
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